This result indicates that HMGA1 depletion was able to sensitize tumours to the treatment and suggests that taxol-based treatments may be more efficacious in reducing the tumour burden when tumour cells expressed low levels of HMGA1. This evidence concerns the gene HMGA1 and neoplasm.